Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1

[1]  P. Haslett,et al.  Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1 , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[2]  J. Lieske,et al.  Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. , 2021, The New England journal of medicine.

[3]  D. Lawlor,et al.  Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria , 2020, eLife.

[4]  W. Lowther,et al.  Endpoints for Clinical Trials in Primary Hyperoxaluria. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[5]  S. Senniappan,et al.  Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria , 2017, Pediatric Nephrology.

[6]  P. Haslett,et al.  An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. , 2017, Journal of the American Society of Nephrology : JASN.

[7]  J. Lieske,et al.  Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. , 2015, Journal of the American Society of Nephrology : JASN.

[8]  T. Vrtiska,et al.  Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria , 2014, Kidney international.

[9]  R. Belostotsky,et al.  Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria , 2014, Journal of Medical Genetics.

[10]  B. Hero,et al.  Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[11]  E. Salido,et al.  Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  M. Galanti,et al.  Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1 , 2010, Pediatric Nephrology.

[13]  D. Abramowicz,et al.  Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. , 2010, Kidney international.

[14]  N. Sebire,et al.  Primary hyperoxaluria type 1 , 2007, Archives of Disease in Childhood.

[15]  E. Bergstralh,et al.  International Registry for Primary Hyperoxaluria , 2005, American Journal of Nephrology.

[16]  R. Wanders,et al.  Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  H. Mandel,et al.  PRIMARY HYPEROXALURIA TYPE 1: IMPROVED OUTCOME WITH TIMELY LIVER TRANSPLANTATION: A SINGLE-CENTER REPORT OF 36 CHILDREN , 2001, Transplantation.

[18]  M. Kemper,et al.  Long‐term results of pre‐emptive liver transplantation in primary hyperoxaluria type 1 , 2000, Pediatric transplantation.

[19]  W. Craigen.  Persistent glycolic aciduria in a healthy child with normal alanine-glyoxylate aminotransferase activity , 1996, Journal of Inherited Metabolic Disease.

[20]  B. Shuckett,et al.  Observer reliability in grading nephrocalcinosis on ultrasound examinations in children , 1996, Pediatric Radiology.

[21]  P. Desmond,et al.  Primary hyperoxaluria type I. , 1994, Australasian radiology.

[22]  P. Cochat,et al.  Primary hyperoxaluria. , 2013, The New England journal of medicine.

[23]  David S. Wishart,et al.  The Online Metabolic and Molecular Bases of Inherited Disease; Chapter 3.1: Metabolism and Metabolic Disease Resources on the Web, Page 1 , 2007 .